Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Université Laval has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 8 distinct examiners and 8 distinct art units. The matching totals show that each pending matter has a separate examiner and art-unit assignment, producing a widely distributed prosecution profile.
FRANKLIN, JODI COHEN is the busiest examiner, with 1 pending matter. No examiner accounts for more than that reported amount, so a centralized examiner strategy would not reflect the available docket structure. Counsel should maintain matter-level records for claim amendments, cited references, interview history, and response deadlines.
The portfolio's examination activity is spread across the reported art units rather than concentrated in one technical assignment. That structure supports a coordinated review framework, but it does not show whether the matters share inventions, claim themes, or substantive objections. File-level analysis remains necessary before adopting common arguments or amendment positions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| Multi-statute (no §101) | 6 (86%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IANNUZO, NATALIE NMN | 1 | 12.2% | +71.4% |
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
| HOFFMAN, ALEXANDER JOSEPH | 1 | 0.0% | +0.0% |
| IQBAL, SYED TAHA | 1 | 80.0% | +21.3% |
| HUSSAIN, MISHAL ZAHRA | 1 | 64.8% | +39.6% |
| KATAKAM, SUDHAKAR | 1 | 74.8% | +23.3% |
| NGUYEN, LAUREN | 1 | 54.8% | +34.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17783539 | ELECTRODE STRUCTURE FOR CREATING ELECTRICAL POTENTIAL GRADIENT | NGUYEN, LAUREN | 29d |
| 18276598 | A Facial Mask Assembly Dispensing a Protective Laminar Airflow | HUSSAIN, MISHAL ZAHRA | 62d |
| 18717027 | BIOMARKERS FOR PROGNOSIS OF EARLY ONSET PREECLAMPSIA | IANNUZO, NATALIE NMN | — |
| 18571101 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | GONZALEZ, LUISALBERTO | — |
| 18563723 | METHODS AND KITS FOR DIAGNOSING SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES | HOFFMAN, ALEXANDER JOSEPH | — |
| 18382191 | BISMUTH-DOPED GERMANOSILICATE FIBER FOR E AND S BAND AMPLIFICATION | IQBAL, SYED TAHA | — |
| 18087433 | PROCESS FOR THE LINEAR SYNTHESIS OF GRAM-POSITIVE CLASS II BACTERIOCINS AND COMPOSITIONS AND USES THEREOF | KATAKAM, SUDHAKAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17783539 | ELECTRODE STRUCTURE FOR CREATING ELECTRICAL POTENTIAL GRADIENT | NGUYEN, LAUREN | 29d |
| 18276598 | A Facial Mask Assembly Dispensing a Protective Laminar Airflow | HUSSAIN, MISHAL ZAHRA | 62d |
| 18717027 | BIOMARKERS FOR PROGNOSIS OF EARLY ONSET PREECLAMPSIA | IANNUZO, NATALIE NMN | — |
| 18571101 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | GONZALEZ, LUISALBERTO | — |
| 18382191 | BISMUTH-DOPED GERMANOSILICATE FIBER FOR E AND S BAND AMPLIFICATION | IQBAL, SYED TAHA | — |
| 18087433 | PROCESS FOR THE LINEAR SYNTHESIS OF GRAM-POSITIVE CLASS II BACTERIOCINS AND COMPOSITIONS AND USES THEREOF | KATAKAM, SUDHAKAR | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1624 | 1 |
| 1677 | 1 |
| 1736 | 1 |
| 3785 | 1 |
| 1658 | 1 |
| 2871 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717027 | BIOMARKERS FOR PROGNOSIS OF EARLY ONSET PREECLAMPSIA | IANNUZO, NATALIE NMN | 1653 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 06, 2024 |
| 18571101 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | GONZALEZ, LUISALBERTO | 1624 | §102§103§112 | Final Rejection | — | Pending | Dec 15, 2023 |
| 18563723 | METHODS AND KITS FOR DIAGNOSING SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES | HOFFMAN, ALEXANDER JOSEPH | 1677 | §103§112 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18382191 | BISMUTH-DOPED GERMANOSILICATE FIBER FOR E AND S BAND AMPLIFICATION | IQBAL, SYED TAHA | 1736 | §102§103 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18276598 | A Facial Mask Assembly Dispensing a Protective Laminar Airflow | HUSSAIN, MISHAL ZAHRA | 3785 | §102§103§112 | Non-Final OA | 62d | Pending | Aug 09, 2023 |
| 18087433 | PROCESS FOR THE LINEAR SYNTHESIS OF GRAM-POSITIVE CLASS II BACTERIOCINS AND COMPOSITIONS AND USES THEREOF | KATAKAM, SUDHAKAR | 1658 | §103§112 | Non-Final OA | — | Pending | Dec 22, 2022 |
| 17783539 | ELECTRODE STRUCTURE FOR CREATING ELECTRICAL POTENTIAL GRADIENT | NGUYEN, LAUREN | 2871 | §103§112 | Non-Final OA | 29d | Pending | Jun 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversité Laval has 7 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
Natalie Nmn Iannuzo has the most, with 1 of Université Laval's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
